Ohcanbohtosat - Debbie Robbrecht
- Čájehuvvo 1 - 3 / 3
-
1
Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial Dahkki Reetta Virtakoivu, Jenna H. Rannikko, Miro Viitala, Felix Vaura, Akira Takeda, Tapio Lönnberg, Jussi Koivunen, Panu Jaakkola, Annika Pasanen, Shishir Shetty, Maja J.A. de Jonge, Debbie Robbrecht, Yuk Ting, Tanja Skyttä, Anna Minchom, Sirpa Jalkanen, Matti K. Karvonen, Jami Mandelin, Petri Bono, Maija Hollmén
Almmustuhtton 2021Artigo -
2
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors Dahkki Neeltje Steeghs, Carlos Gomez‐Roca, Kristoffer Staal Rohrberg, Morten Mau‐Sørensen, Debbie Robbrecht, Josep Tabernero, Samreen Ahmed, María E. Rodríguez-Ruiz, Caroline Ardeshir, Daniela Schmid, Nassim Sleiman, Carl Watson, Hanna Piper-Lepoutre, David Dejardin, Stefan Evers, Christophe Boetsch, Jehad Charo, Volker Teichgräber, Ignacio Melero
Almmustuhtton 2024Artigo -
3
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: The phase I/II first-in-human MATINS trial Dahkki Jenna H. Rannikko, Loïc Verlingue, Maria J. de Miguel, Annika Pasanen, Debbie Robbrecht, Tanja Skyttä, Sanna Iivanainen, Shishir Shetty, Yuk Ting, Donna M. Graham, Sukeshi Patel Arora, Panu Jaakkola, Christina Yap, Yujuan Xiang, Jami Mandelin, Matti K. Karvonen, Juho Jalkanen, Sinem Karaman, Jussi Koivunen, Anna Minchom, Maija Hollmén, Petri Bono
Almmustuhtton 2023Artigo
Ohcanreaiddut:
Laktáseaddji fáttát
Cancer
Internal medicine
Medicine
Blockade
Cancer research
Receptor
Solid tumor
Adverse effect
Biology
Breast cancer
Clinical trial
Downregulation and upregulation
Gene
Genetics
Immune checkpoint
Immunology
Immunotherapy
Melanoma
Oncology
Pathology
Pharmacodynamics
Pharmacokinetics
Pharmacology
Tolerability